SCHEMBL6296360

SCHEMBL6296360

COc1cccc(/C=C/C(=O)c2ccccn2)c1OC

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KRAS P01116 1/20 0.67
▸ NFE2L2 Q16236 2/20 0.62
▸ CYP1A1 P04798 3/20 0.58
▸ CYP1A2 P05177 3/20 0.58
▸ CYP2D6 P10635 3/20 0.58
▸ ALOX5 P09917 1/20 0.58
▸ NPC1 O15118 3/20 0.57
▸ MAPT P10636 3/20 0.57
▸ RAB9A P51151 3/20 0.57
▸ ALDH1A1 P00352 2/20 0.57
▸ KDM4E B2RXH2 2/20 0.57
▸ PKM P14618 2/20 0.57
▸ MEN1 O00255 1/20 0.57
▸ KMT2A Q03164 1/20 0.57
▸ L3MBTL1 Q9Y468 1/20 0.57
▸ MAOB P27338 2/20 0.56
▸ TRPM8 Q7Z2W7 2/20 0.55
▸ LMNA P02545 3/20 0.55
▸ NTSR1 P30989 1/20 0.55
▸ TDP1 Q9NUW8 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6296362 1.00 KRAS (0.67) KRASNFE2L2CYP1A1CYP1A2CYP2D6
SCHEMBL6292941 0.89 NPC1 (0.67) KRASNFE2L2CYP1A1CYP1A2CYP2D6
SCHEMBL6292944 0.89 NPC1 (0.67) KRASNFE2L2CYP1A1CYP1A2CYP2D6
SCHEMBL6292943 0.84 KRAS (0.66) KRASNFE2L2CYP1A1CYP1A2CYP2D6
SCHEMBL6292945 0.84 KRAS (0.66) KRASNFE2L2CYP1A1CYP1A2CYP2D6
SCHEMBL4026900 0.82 LMNA (0.78) NFE2L2CYP1A1CYP1A2CYP2D6ALOX5
SCHEMBL1764951 0.80 NFE2L2 (0.70) NFE2L2CYP1A1CYP1A2CYP2D6ALOX5
SCHEMBL19183192 0.79 NFE2L2 (0.74) NFE2L2CYP1A1CYP1A2CYP2D6ALOX5
SCHEMBL19183189 0.79 NFE2L2 (0.74) NFE2L2CYP1A1CYP1A2CYP2D6ALOX5
SCHEMBL6295704 0.79 MAPT (0.70) KRASCYP1A1CYP1A2CYP2D6NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6846817-B2 Nicotine receptor ligands REGENTS OF THE UNIVERSITY OF MINNESOTA (US) 2005-01-25 — — US disclosed
US-20030027810-A1 Nicotine receptor ligands REGENTS OF THE UNIVERSITY OF MINNESOTA 2003-02-06 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030027810-A1 Nicotine receptor ligands CHRNA1, CHRNB1, CHRNA9 KRAS 1316/4885NFE2L2 4254/4885CYP1A1 845/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback